Pirtobrutinib Clinical Trials
29 recruitingDrug
Phase 221Phase 33Phase 13Phase 43Early Phase 11
Showing 1–20 of 29 trials
Recruiting
Phase 3
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
BeOne Medicines500 enrolled154 locationsNCT06973187
Recruiting
Phase 4
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaLymphoma, Small Lymphocytic
Eli Lilly and Company150 enrolled53 locationsNCT07218341
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled131 locationsNCT06588478
Recruiting
Phase 3
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
CLLCLL/SLLCLL (Chronic Lymphocytic Leukemia)+5 more
Newave Pharmaceutical Inc306 enrolled4 locationsNCT07342478
Recruiting
Phase 1Phase 2
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Non-Hodgkin LymphomaHematologic MalignancyMantle Cell Lymphoma
M.D. Anderson Cancer Center30 enrolled1 locationNCT05529069
Recruiting
Phase 2
Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
Leukemia
M.D. Anderson Cancer Center60 enrolled1 locationNCT05536349
Recruiting
Phase 2
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
Mantle Cell Lymphoma
M.D. Anderson Cancer Center50 enrolled1 locationNCT06263491
Recruiting
Phase 3
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaLeukemia, B-cell+1 more
Loxo Oncology, Inc.662 enrolled144 locationsNCT05254743
Recruiting
Phase 2
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
Recurrent Follicular LymphomaRefractory Follicular LymphomaGrade 1 Follicular Lymphoma+2 more
University of Washington22 enrolled1 locationNCT06948786
Recruiting
Phase 2
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
Mantle Cell Lymphoma
University of California, San Francisco30 enrolled3 locationsNCT06252675
Recruiting
Phase 2
Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute60 enrolled3 locationsNCT06553872
Recruiting
Early Phase 1
Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
National Heart, Lung, and Blood Institute (NHLBI)30 enrolled1 locationNCT07428707
Recruiting
Phase 4
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company787 enrolled38 locationsNCT06876649
Recruiting
Phase 4
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma
Eli Lilly and Company279 enrolled36 locationsNCT06876662
Recruiting
Phase 2
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
Mantle Cell Lymphoma
M.D. Anderson Cancer Center40 enrolled2 locationsNCT06522386
Recruiting
Phase 1
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+3 more
Medical College of Wisconsin12 enrolled1 locationNCT05990465
Recruiting
Phase 2
Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Kerry Rogers30 enrolled1 locationNCT06466122
Recruiting
Phase 2
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Lymphoma, Non-HodgkinB-cell LymphomaLeukemia, Lymphocytic, Chronic, B-Cell
Eli Lilly and Company13 enrolled6 locationsNCT07162181
Recruiting
Phase 2
Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Inhye Ahn60 enrolled4 locationsNCT06333262